Quizzes for review
Niraparib was selected because it was the only PARPi in clinical trials with temozolomide at the time of this study, and rucaparib and BMN-673 were selected because they are potent PARP trappers.
音声機能が動作しない場合はこちらをご確認ください
English - English
Word Edit Setting
- Users who have edit permission for words - All Users
- Screen new word creation
- Screen word edits
- Screen word deletion
- Screen the creation of new headword that may be duplicates
- Screen changing entry name
- Users authorized to vote on judging - Editor
- Number of votes required for decision - 1
Sentence Edit Setting
- Users who have edit permission for sentences - All Users
- Screen sentence deletion
- Users authorized to vote on judging - Editor
- Number of votes required for decision - 1
Quiz Edit Setting
- Users who have edit permission for quizzes - All Users
- Users authorized to vote on judging - Editor
- Number of votes required for decision - 1
